The methodology involved a comparative analysis of methylation levels at a specific CpG dinucleotide within the SPDEF promoter region (chr6:34544344–34544482) in DNA extracted from whole blood leukocytes of PCa patients and BPH controls. Here, SPDEF is linked to benign prostatic hyperplasia.